Sino Biopharm Surges After Striking Over USD7 Billion Cancer Drug Deal With Boehringer IngelheimYicai·Nov 5, 2026 at 03:19 AM01177+9.22%
BeOne Medicines Publishes Clinical Trial Portfolio PresentationPUBT·Nov 5, 2026 at 11:29 AM06160+7.34%688235+3.84%
BeOne Medicines climbs 5% as Brukinsa gets FDA priority reviewMarket Movers·Nov 5, 2026 at 01:45 AM06160+7.34%
Akeso's Ivonescimab Gets China Priority Review for First-Line Biliary Tract CancerPUBT·Nov 5, 2026 at 04:20 AM09926+6.48%
BeOne Medicines Reports Unaudited Third-Quarter 2026 ResultsTip Ranks·Nov 5, 2026 at 11:54 AMBGNE0.00%06160+7.34%
Boehringer signs oncology deal with Sino Biopharm worth up to $7.4bnPharmaceutical Technology·Nov 4, 2026 at 11:39 AM01177+9.22%
SBP GROUP Reaches Collaboration With Boehringer Ingelheim, Potential Proceeds USD7 BillionAASTOCKS News·Nov 4, 2026 at 08:55 AM01177+9.22%
CSPC Pharmaceutical starts Phase I/II trial of SYS6062 for advanced solid tumors in ChinaPUBT·Nov 5, 2026 at 10:25 AM01093+2.63%
CSPC Pharmaceutical Starts Phase II Trial of SYH2072 for Hypertension in ChinaPUBT·Nov 3, 2026 at 10:26 AM01093+2.63%
Citi Sticks to Their Buy Rating for Wuxi Biologics (Cayman) (WXIBF)Tip Ranks·Nov 5, 2026 at 12:27 AMWXXWY-1.84%02269+0.75%
WuXi Biologics Wins Two Grand Awards at 2026 Hong Kong ESG Reporting AwardsPUBT·Nov 4, 2026 at 03:04 AM02269+0.75%
ASIA MIDDAY MOVES | Nikkei Falls Over 4%, Taiwan Stocks Briefly Lose 42,000 as U.S. Midterm Counts WeighCoinLive·Nov 4, 2026 at 04:33 AMJD+3.28%NIO-3.03%
Bernstein Sticks to Their Buy Rating for Hansoh Pharmaceutical Group Company Limited (3692)Tip Ranks·Nov 3, 2026 at 10:26 AM03692+3.11%